The global Friedreich’s ataxia market is experiencing notable growth, fueled by advancements in genetic research, enhanced diagnostic technologies, and increased awareness of this rare ...

Editor’s note: This is an automatically generated transcript, which has been slightly edited for clarity. Please notify [email protected] if there are concerns regarding accuracy of the transcription.

Lexeo Therapeutics, Inc. surges after FDA trial alignment for LX2006 in Friedreich’s ataxia. Click for more on LXEO stock following its Q3 earnings release.

Biohaven is proposing troriluzole for the treatment of spinocerebellar ataxia, a group of rare, genetic diseases that lead to ...

The FDA has issued a CRL to Biohaven regarding the NDA for troriluzole for the treatment of adults with spinocerebellar ataxia.

Some cats wobble, fall over constantly, and generally have no control over their movements. These cats live with the ...

European Commission approves OMP Designation for NLX-112 (befiradol) following compelling results in studies funded by the US Dept of Defense. This OMP designation is a milestone for Neurolixis as we ...

Biohaven's troriluzole candidate for spinocerebellar ataxia (SCA) has been turned down by the FDA, causing shares in the company to lose more than 40% of their value in pre-market trading.

Detailed price information for Solid Biosciences Inc (SLDB-Q) from The Globe and Mail including charting and trades.

After the FDA rejected its spinocerebellar ataxia treatment, Biohaven missed out on a $150 million payment from Oberland Capital. Now the company is reshuffling its pipeline to stay alive.

Medical experts use the term “cerebellar ataxia” when referring to conditions that lead to a lack of muscle control. Dysmetria is one form of cerebellar ataxia. Dysmetria occurs due to the improper ...